Clinical Trials Browser

siltuximab × Lymphoid × Clear all

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Phase 1 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

NCT05665725 2025-01-31

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Phase EARLY_PHASE1 Withdrawn

Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Phase 1 Completed

LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma